Novartis: FDA grants priority review to lung cancer drug
(CercleFinance.com) - Novartis said that US health regulators have granted a priority review to its experimental drug capmatinib for the treatment of a specific form of advanced non-small cell lung cancer, accelerating the drug's review process.
The Food and Drug Administration (FDA) has granted priority review to capmatinib's new drug application as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer.
If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.
The review is expected to be completed within six months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Food and Drug Administration (FDA) has granted priority review to capmatinib's new drug application as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer.
If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.
The review is expected to be completed within six months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.